Advanced systemic mastocytosis is a progressive disorder that causes the atypical buildup of mast cells in different organs in the body. Treatment aims to slow the progression of the condition and ...

A diagnosis of advanced systemic mastocytosis (advSM), a rare blood disorder in which too many mast cells accumulate in various parts of the body, can cause a range of strong emotions. AdvSM sometimes ...

Advanced systemic mastocytosis is a progressive condition characterized by the accumulation of mast cells in the body’s organs. There’s no cure for advanced systemic mastocytosis, but many of the ...

Advanced systemic mastocytosis comprises rare hematologic neoplasms that are associated with a poor prognosis and lack effective treatment options. The multikinase inhibitor midostaurin inhibits KIT ...

The Food and Drug Administration (FDA) has approved Ayvakit™ (avapritinib) for the treatment of adults with advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis, ...

Bone disease is a significant yet often underrecognized comorbidity in patients with systemic mastocytosis. Diagnosing and managing bone health in this patient population is challenging due to ...

Systemic mastocytosis (SM) is a rare blood disorder in which the body produces too many mast cells. Part of the immune response, mast cells are a type of white blood cell that releases histamine in ...

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer Patients with AdvSM (n = ...

(RTTNews) - Blueprint Medicines Corp. (BPMC) said Friday that the European Commission has expanded the current indication for AYVAKYT (avapritinib) to include monotherapy for the treatment of adult ...